<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531673</url>
  </required_header>
  <id_info>
    <org_study_id>VX11-661-101</org_study_id>
    <secondary_id>2011-003821-93</secondary_id>
    <nct_id>NCT01531673</nct_id>
  </id_info>
  <brief_title>Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation</brief_title>
  <official_title>A Phase 2, Multicenter, Double-Blinded, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/Ivacaftor Cotherapy in Subjects With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (PK), and
      pharmacodynamics (PD) effects of VX-661 alone and when coadministered with ivacaftor in
      participants with cystic fibrosis (CF) who are homozygous or heterozygous for the
      F508del-CFTR mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, randomized, multicenter, double-blinded, placebo-controlled, study of
      VX-661 monotherapy, and VX-661/ivacaftor co-therapy in participants with CF who are
      homozygous or heterozygous for the F508del CFTR mutation.

      This study is separated into seven groups: Group 1-7, respectively. Approximately 180
      participants were randomized in a ratio of 4:1; active drug to matching placebo in each
      group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as Determined by Adverse Events (AEs)</measure>
    <time_frame>Start of study drug through the Follow-up Visit (Up to Day 56)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the Informed Consent Form is signed. AE includes serious as well as non-serious AEs. Serious Adverse Event (SAE) is any AE that results in any of the following: death; life-threatening condition; inpatient hospitalization or prolongation of hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; or other important medical event. Treatment-emergent adverse events are defined as adverse events that were reported or worsened on or after start of study drug through the Follow-up Visit (28 days after last dose of study drug) or premature discontinuation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Sweat Chloride From Baseline Through Study Day 28 for Group 6</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Sweat Chloride From Baseline Through Study Day 28 for Group 7</measure>
    <time_frame>Baseline through Day 28</time_frame>
    <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 1-5b</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
    <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 6</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
    <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 7</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
    <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 (Liter [L]) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7</measure>
    <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b</measure>
    <time_frame>Baseline, Day 14, Day 28</time_frame>
    <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6</measure>
    <time_frame>Baseline, Day 14, Day 28</time_frame>
    <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7</measure>
    <time_frame>Baseline, Day 14, Day 28</time_frame>
    <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 After Administration of VX-661 Monotherapy</measure>
    <time_frame>Day 28</time_frame>
    <description>Participants who received VX-661 monotherapy (Group 1, 2a, 3a and 5a) were analyzed for this outcome measure. PK analysis (AUC0-24h) was not planned for placebo reporting arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24h of VX-661 and AUC0-12h of Ivacaftor After Administration of VX-661 in Combination With Ivacaftor</measure>
    <time_frame>Day 28</time_frame>
    <description>Participants who received VX-661 in combination with Ivacaftor (Group 2b, 3b, 4, 5b, 6a, 6d and 7) were analyzed for this outcome measure. PK analysis was not planned for placebo reporting arms.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Group 1-6d Combined: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: VX-661 10 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a: VX-661 30 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3a: VX-661 100 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5a: VX-661 150 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: VX-661 100 mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco (Ivacaftor) for up to 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-661</intervention_name>
    <arm_group_label>Group 1: VX-661 10 mg qd</arm_group_label>
    <arm_group_label>Group 2a: VX-661 30 mg qd</arm_group_label>
    <arm_group_label>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 3a: VX-661 100 mg qd</arm_group_label>
    <arm_group_label>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 5a: VX-661 150 mg qd</arm_group_label>
    <arm_group_label>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</arm_group_label>
    <arm_group_label>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 7: VX-661 100 mg qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <arm_group_label>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</arm_group_label>
    <arm_group_label>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</arm_group_label>
    <arm_group_label>Group 7: Placebo</arm_group_label>
    <arm_group_label>Group 7: VX-661 100 mg qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matched to VX-661</intervention_name>
    <arm_group_label>Group 1-6d Combined: Placebo</arm_group_label>
    <arm_group_label>Group 7: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matched to ivacaftor</intervention_name>
    <arm_group_label>Group 1-6d Combined: Placebo</arm_group_label>
    <arm_group_label>Group 2a: VX-661 30 mg qd</arm_group_label>
    <arm_group_label>Group 3a: VX-661 100 mg qd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female with confirmed diagnosis of CF

          -  Must have the F508del-CFTR gene mutation in both alleles (Groups 1, 2, 3, 4, 5, 6).
             Group 7 participants must have the F508del-CFTR mutation on 1 allele, and gating
             mutation G551D on the second allele and have been on their physician prescribed 150 mg
             KalydecoTM q12h (commercially available ivacaftor) for at least 28 days at the
             Screening Visit.

          -  Forced expiratory volume in 1 second(FEV1) 40% to 90% (inclusive) of predicted normal
             for age, gender, and height (Knudson standards) at screening

          -  Weight &gt;40 kg and BMI &gt;18.5

          -  Participants of child-bearing potential and who are sexually active must meet the
             contraception requirements.

        Exclusion Criteria:

          -  History of any illness that, in the opinion of the investigator, might confound the
             results of the study or pose an additional risk in administering study drug to the
             participant.

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 4 weeks before Study Day
             1.

          -  History of solid organ or hematological transplantation

          -  Participation in a clinical study involving administration of either an
             investigational or a marketed drug within 30 days or 5 terminal half-lives (whichever
             is longer) before screening

          -  History of alcohol, medication, or illicit drug abuse within 1 year prior to screening

          -  Pregnant, breast-feeding, or not willing to follow contraception requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Donaldson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Bochum</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Southhampton</city>
        <state>Hampshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vertex Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <state>Vale Of Glamorgen</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <results_first_submitted>March 14, 2018</results_first_submitted>
  <results_first_submitted_qc>March 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <disposition_first_submitted>May 5, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 5, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 22, 2015</disposition_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 194 participants were randomized of which 190 participants were treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1-6d Combined: Placebo</title>
          <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
        </group>
        <group group_id="P2">
          <title>Group 1: VX-661 10 mg qd</title>
          <description>All participants in group 1 who received VX-661 10 milligram (mg) tablet orally once daily (qd) for up to 28 days.</description>
        </group>
        <group group_id="P3">
          <title>Group 2a: VX-661 30 mg qd</title>
          <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet every 12 hours (q12h) for up to 28 days.</description>
        </group>
        <group group_id="P4">
          <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="P5">
          <title>Group 3a: VX-661 100 mg qd</title>
          <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
        </group>
        <group group_id="P6">
          <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="P7">
          <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="P8">
          <title>Group 5a: VX-661 150 mg qd</title>
          <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
        </group>
        <group group_id="P9">
          <title>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="P10">
          <title>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</title>
          <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="P11">
          <title>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="P12">
          <title>Group 7: Placebo</title>
          <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
        </group>
        <group group_id="P13">
          <title>Group 7: VX-661 100 mg qd</title>
          <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="19"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="17"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="17"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="4"/>
                <participants group_id="P13" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1-6d Combined: Placebo</title>
          <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
        </group>
        <group group_id="B2">
          <title>Group 1: VX-661 10 mg qd</title>
          <description>All participants in group 1 who received VX-661 10 mg tablet orally qd for up to 28 days.</description>
        </group>
        <group group_id="B3">
          <title>Group 2a: VX-661 30 mg qd</title>
          <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
        </group>
        <group group_id="B4">
          <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="B5">
          <title>Group 3a: VX-661 100 mg qd</title>
          <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
        </group>
        <group group_id="B6">
          <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="B7">
          <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="B8">
          <title>Group 5a: VX-661 150 mg qd</title>
          <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
        </group>
        <group group_id="B9">
          <title>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="B10">
          <title>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</title>
          <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="B11">
          <title>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="B12">
          <title>Group 7: Placebo</title>
          <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
        </group>
        <group group_id="B13">
          <title>Group 7: VX-661 100 mg qd</title>
          <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
        </group>
        <group group_id="B14">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="18"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="19"/>
            <count group_id="B7" value="17"/>
            <count group_id="B8" value="9"/>
            <count group_id="B9" value="17"/>
            <count group_id="B10" value="19"/>
            <count group_id="B11" value="16"/>
            <count group_id="B12" value="4"/>
            <count group_id="B13" value="14"/>
            <count group_id="B14" value="190"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.7" spread="8.42"/>
                    <measurement group_id="B2" value="35.3" spread="8.26"/>
                    <measurement group_id="B3" value="30.8" spread="6.63"/>
                    <measurement group_id="B4" value="28.3" spread="7.05"/>
                    <measurement group_id="B5" value="29.1" spread="7.12"/>
                    <measurement group_id="B6" value="29.2" spread="6.39"/>
                    <measurement group_id="B7" value="31" spread="9.3"/>
                    <measurement group_id="B8" value="28.2" spread="8.6"/>
                    <measurement group_id="B9" value="28.2" spread="6.46"/>
                    <measurement group_id="B10" value="27.9" spread="5.58"/>
                    <measurement group_id="B11" value="32.8" spread="11.92"/>
                    <measurement group_id="B12" value="34.5" spread="7.59"/>
                    <measurement group_id="B13" value="26.6" spread="7.01"/>
                    <measurement group_id="B14" value="29.8" spread="7.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="6"/>
                    <measurement group_id="B14" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="12"/>
                    <measurement group_id="B11" value="9"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="8"/>
                    <measurement group_id="B14" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety as Determined by Adverse Events (AEs)</title>
        <description>An AE is defined as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the Informed Consent Form is signed. AE includes serious as well as non-serious AEs. Serious Adverse Event (SAE) is any AE that results in any of the following: death; life-threatening condition; inpatient hospitalization or prolongation of hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; or other important medical event. Treatment-emergent adverse events are defined as adverse events that were reported or worsened on or after start of study drug through the Follow-up Visit (28 days after last dose of study drug) or premature discontinuation.</description>
        <time_frame>Start of study drug through the Follow-up Visit (Up to Day 56)</time_frame>
        <population>Analysis was done using safety set which included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1-6d Combined: Placebo</title>
            <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 1: VX-661 10 mg qd</title>
            <description>All participants in group 1 who received VX-661 10 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 2a: VX-661 30 mg qd</title>
            <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Group 3a: VX-661 100 mg qd</title>
            <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O7">
            <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O8">
            <title>Group 5a: VX-661 150 mg qd</title>
            <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O10">
            <title>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</title>
            <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O11">
            <title>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O12">
            <title>Group 7: Placebo</title>
            <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
          <group group_id="O13">
            <title>Group 7: VX-661 100 mg qd</title>
            <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety as Determined by Adverse Events (AEs)</title>
          <description>An AE is defined as any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the Informed Consent Form is signed. AE includes serious as well as non-serious AEs. Serious Adverse Event (SAE) is any AE that results in any of the following: death; life-threatening condition; inpatient hospitalization or prolongation of hospitalization; persistent or significant disability or incapacity; congenital anomaly or birth defect; or other important medical event. Treatment-emergent adverse events are defined as adverse events that were reported or worsened on or after start of study drug through the Follow-up Visit (28 days after last dose of study drug) or premature discontinuation.</description>
          <population>Analysis was done using safety set which included all participants who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="17"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="17"/>
                <count group_id="O10" value="19"/>
                <count group_id="O11" value="16"/>
                <count group_id="O12" value="4"/>
                <count group_id="O13" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="18"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="16"/>
                    <measurement group_id="O11" value="16"/>
                    <measurement group_id="O12" value="2"/>
                    <measurement group_id="O13" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                    <measurement group_id="O11" value="2"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b</title>
        <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
        <time_frame>Baseline through Day 28</time_frame>
        <population>The analysis was done using Full Analysis Set (FAS) which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VX-661 10 mg qd</title>
            <description>All participants in group 1 who received VX-661 10 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2a: VX-661 30 mg qd</title>
            <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Group 3a: VX-661 100 mg qd</title>
            <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O7">
            <title>Group 5a: VX-661 150 mg qd</title>
            <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O8">
            <title>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Group 1-5b Combined Placebo</title>
            <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a and 5b who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sweat Chloride From Baseline Through Study Day 28 for Group 1-5b</title>
          <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
          <population>The analysis was done using Full Analysis Set (FAS) which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint.</population>
          <units>millimole per liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="17"/>
                <count group_id="O9" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" lower_limit="-0.5" upper_limit="8.34"/>
                    <measurement group_id="O2" value="-4.76" lower_limit="-9.75" upper_limit="0.22"/>
                    <measurement group_id="O3" value="-5.06" lower_limit="-8.02" upper_limit="-2.09"/>
                    <measurement group_id="O4" value="-20.43" lower_limit="-24.75" upper_limit="-16.12"/>
                    <measurement group_id="O5" value="-6" lower_limit="-8.98" upper_limit="3.02"/>
                    <measurement group_id="O6" value="-6.04" lower_limit="-9.12" upper_limit="-2.96"/>
                    <measurement group_id="O7" value="-10.46" lower_limit="-14.53" upper_limit="-6.39"/>
                    <measurement group_id="O8" value="-2.63" lower_limit="-5.67" upper_limit="0.41"/>
                    <measurement group_id="O9" value="-0.86" lower_limit="-3.36" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0647</p_value>
            <method>Mixed-effect repeated measure (MMRM)</method>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>4.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>9.84</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1686</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>1.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0348</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-19.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.57</ci_lower_limit>
            <ci_upper_limit>-14.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0101</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.03</ci_lower_limit>
            <ci_upper_limit>-1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-5.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.16</ci_lower_limit>
            <ci_upper_limit>-1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-9.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.38</ci_lower_limit>
            <ci_upper_limit>-4.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3745</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.71</ci_lower_limit>
            <ci_upper_limit>2.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Sweat Chloride From Baseline Through Study Day 28 for Group 6</title>
        <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
        <time_frame>Baseline through Day 28</time_frame>
        <population>The analysis was done using Full Analysis Set (FAS) which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</title>
            <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 6d who received VX-661 50 mg tablet q12h and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 and 6 Combined: Placebo</title>
            <description>All participants in group 4, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sweat Chloride From Baseline Through Study Day 28 for Group 6</title>
          <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
          <population>The analysis was done using Full Analysis Set (FAS) which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.07" lower_limit="-10.84" upper_limit="-1.31"/>
                    <measurement group_id="O2" value="-7.89" lower_limit="-12.3" upper_limit="-3.48"/>
                    <measurement group_id="O3" value="-1.19" lower_limit="-5.5" upper_limit="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0357</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.94</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Sweat Chloride From Baseline Through Study Day 28 for Group 7</title>
        <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
        <time_frame>Baseline through Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 7: Placebo</title>
            <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 7: VX-661 100 mg qd</title>
            <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sweat Chloride From Baseline Through Study Day 28 for Group 7</title>
          <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.18" lower_limit="-2.48" upper_limit="22.84"/>
                    <measurement group_id="O2" value="-7.02" lower_limit="-14.15" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0238</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-17.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.75</ci_lower_limit>
            <ci_upper_limit>-2.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 1-5b</title>
        <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint and Number Analyzed = those participants who were evaluable at the specified time points for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VX-661 10 mg qd</title>
            <description>All participants in group 1 who received VX-661 10 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2a: VX-661 30 mg qd</title>
            <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Group 3a: VX-661 100 mg qd</title>
            <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O7">
            <title>Group 5a: VX-661 150 mg qd</title>
            <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O8">
            <title>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Group 1-5b Combined Placebo</title>
            <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a and 5b who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 1-5b</title>
          <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint and Number Analyzed = those participants who were evaluable at the specified time points for each arm, respectively.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="18"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="17"/>
                <count group_id="O9" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="-3.82" upper_limit="7.29"/>
                    <measurement group_id="O2" value="-3.13" lower_limit="-9.5" upper_limit="3.25"/>
                    <measurement group_id="O3" value="-5.37" lower_limit="-9.24" upper_limit="-1.49"/>
                    <measurement group_id="O4" value="-19.48" lower_limit="-25" upper_limit="-13.97"/>
                    <measurement group_id="O5" value="-5.02" lower_limit="-8.85" upper_limit="-1.19"/>
                    <measurement group_id="O6" value="-6.85" lower_limit="-10.72" upper_limit="-2.99"/>
                    <measurement group_id="O7" value="-13.89" lower_limit="-19.09" upper_limit="-8.69"/>
                    <measurement group_id="O8" value="-0.59" lower_limit="-4.38" upper_limit="3.2"/>
                    <measurement group_id="O9" value="0.22" lower_limit="-3.01" upper_limit="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="14"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" lower_limit="-4.64" upper_limit="6.46"/>
                    <measurement group_id="O2" value="-7.88" lower_limit="-14.25" upper_limit="-1.5"/>
                    <measurement group_id="O3" value="-6.55" lower_limit="-10.34" upper_limit="-2.76"/>
                    <measurement group_id="O4" value="-28.23" lower_limit="-33.75" upper_limit="22.72"/>
                    <measurement group_id="O5" value="-6.77" lower_limit="-10.81" upper_limit="-2.74"/>
                    <measurement group_id="O6" value="-7.37" lower_limit="-11.44" upper_limit="-3.3"/>
                    <measurement group_id="O7" value="-10.28" lower_limit="-15.48" upper_limit="-5.08"/>
                    <measurement group_id="O8" value="-2.4" lower_limit="-6.38" upper_limit="1.58"/>
                    <measurement group_id="O9" value="-1.32" lower_limit="-4.5" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.84" lower_limit="-0.99" upper_limit="10.66"/>
                    <measurement group_id="O2" value="-4.61" lower_limit="-10.98" upper_limit="1.76"/>
                    <measurement group_id="O3" value="-3.7" lower_limit="-7.48" upper_limit="0.09"/>
                    <measurement group_id="O4" value="-18.78" lower_limit="-24.3" upper_limit="-13.27"/>
                    <measurement group_id="O5" value="-5.83" lower_limit="-9.77" upper_limit="-1.89"/>
                    <measurement group_id="O6" value="-4.26" lower_limit="-8.44" upper_limit="-0.08"/>
                    <measurement group_id="O7" value="-12.17" lower_limit="-17.37" upper_limit="-6.97"/>
                    <measurement group_id="O8" value="-3.9" lower_limit="-7.88" upper_limit="0.08"/>
                    <measurement group_id="O9" value="-1.05" lower_limit="-4.29" upper_limit="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="16"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="15"/>
                    <count group_id="O9" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.19" lower_limit="2.37" upper_limit="14.02"/>
                    <measurement group_id="O2" value="-3.44" lower_limit="-9.82" upper_limit="2.93"/>
                    <measurement group_id="O3" value="-4.62" lower_limit="-8.41" upper_limit="-0.83"/>
                    <measurement group_id="O4" value="-15.23" lower_limit="-20.75" upper_limit="-9.72"/>
                    <measurement group_id="O5" value="-6.37" lower_limit="-10.22" upper_limit="-2.52"/>
                    <measurement group_id="O6" value="-5.68" lower_limit="-9.76" upper_limit="-1.61"/>
                    <measurement group_id="O7" value="-5.5" lower_limit="-10.7" upper_limit="0.3"/>
                    <measurement group_id="O8" value="-3.62" lower_limit="-7.6" upper_limit="0.36"/>
                    <measurement group_id="O9" value="-1.27" lower_limit="-4.55" upper_limit="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 6</title>
        <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint and Number Analyzed = those participants who were evaluable at the specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</title>
            <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 and 6 Combined: Placebo</title>
            <description>All participants in group 4, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 6</title>
          <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number of participants analyzed = those participants who were evaluable for this endpoint and Number Analyzed = those participants who were evaluable at the specified time points for each group, respectively.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.61" lower_limit="-12.06" upper_limit="-1.16"/>
                    <measurement group_id="O2" value="-11.04" lower_limit="-16.37" upper_limit="-5.7"/>
                    <measurement group_id="O3" value="-0.36" lower_limit="-5.54" upper_limit="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" lower_limit="-13.25" upper_limit="-2.55"/>
                    <measurement group_id="O2" value="-7.11" lower_limit="-12.34" upper_limit="-1.88"/>
                    <measurement group_id="O3" value="-2.1" lower_limit="-7.19" upper_limit="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.34" lower_limit="-12" upper_limit="0.68"/>
                    <measurement group_id="O2" value="-6.98" lower_limit="-12.2" upper_limit="-1.76"/>
                    <measurement group_id="O3" value="-2.47" lower_limit="-7.67" upper_limit="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.44" lower_limit="-8.85" upper_limit="1.97"/>
                    <measurement group_id="O2" value="-6.43" lower_limit="-11.55" upper_limit="-1.31"/>
                    <measurement group_id="O3" value="0.19" lower_limit="-5.01" upper_limit="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 7</title>
        <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number Analyzed = those participants who were evaluable at the specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 7: Placebo</title>
            <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 7: VX-661 100 mg qd</title>
            <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sweat Chloride From Baseline to Each Visit up to Study Day 28 for Group 7</title>
          <description>Sweat samples were collected using an approved collection device. Baseline was defined as the most recent non-missing measurement collected before initial administration of study drug.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number Analyzed = those participants who were evaluable at the specified time points for each group, respectively.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.87" lower_limit="-8.32" upper_limit="18.06"/>
                    <measurement group_id="O2" value="-7.28" lower_limit="-14.76" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.75" lower_limit="-2.44" upper_limit="23.94"/>
                    <measurement group_id="O2" value="-8.95" lower_limit="-16.54" upper_limit="-1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.37" lower_limit="-3.82" upper_limit="22.56"/>
                    <measurement group_id="O2" value="-4.14" lower_limit="-11.86" upper_limit="3.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.73" lower_limit="1.85" upper_limit="29.61"/>
                    <measurement group_id="O2" value="-7.72" lower_limit="-15.31" upper_limit="-0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number Analyzed = those participants who were evaluable at the specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VX-661 10 mg qd</title>
            <description>All participants in group 1 who received VX-661 10 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2a: VX-661 30 mg qd</title>
            <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Group 3a: VX-661 100 mg qd</title>
            <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O7">
            <title>Group 5a: VX-661 150 mg qd</title>
            <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O8">
            <title>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Group 1-5b Combined Placebo</title>
            <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a and 5b who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number Analyzed = those participants who were evaluable at the specified time points for each group, respectively.</population>
          <units>percent predicted of FEV1</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="17"/>
                <count group_id="O9" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Baseline Through Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" lower_limit="0.21" upper_limit="6.77"/>
                    <measurement group_id="O2" value="1.63" lower_limit="-1.62" upper_limit="4.87"/>
                    <measurement group_id="O3" value="1.3" lower_limit="-0.87" upper_limit="3.47"/>
                    <measurement group_id="O4" value="1.6" lower_limit="-1.64" upper_limit="4.85"/>
                    <measurement group_id="O5" value="2.9" lower_limit="0.76" upper_limit="5.03"/>
                    <measurement group_id="O6" value="3.75" lower_limit="1.47" upper_limit="6.02"/>
                    <measurement group_id="O7" value="2.54" lower_limit="-0.53" upper_limit="5.61"/>
                    <measurement group_id="O8" value="3.61" lower_limit="1.36" upper_limit="5.86"/>
                    <measurement group_id="O9" value="-0.14" lower_limit="-2.02" upper_limit="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" lower_limit="-1.17" upper_limit="6.62"/>
                    <measurement group_id="O2" value="0.8" lower_limit="-3.09" upper_limit="4.69"/>
                    <measurement group_id="O3" value="0.47" lower_limit="-2.13" upper_limit="3.06"/>
                    <measurement group_id="O4" value="3" lower_limit="-0.89" upper_limit="6.89"/>
                    <measurement group_id="O5" value="2.9" lower_limit="0.37" upper_limit="5.42"/>
                    <measurement group_id="O6" value="2.66" lower_limit="-0.01" upper_limit="5.33"/>
                    <measurement group_id="O7" value="0.5" lower_limit="-3.17" upper_limit="4.18"/>
                    <measurement group_id="O8" value="2.51" lower_limit="-0.16" upper_limit="5.18"/>
                    <measurement group_id="O9" value="-0.41" lower_limit="-2.66" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.25" lower_limit="1.35" upper_limit="9.15"/>
                    <measurement group_id="O2" value="3.72" lower_limit="-0.17" upper_limit="7.61"/>
                    <measurement group_id="O3" value="0.91" lower_limit="-1.69" upper_limit="3.5"/>
                    <measurement group_id="O4" value="1.61" lower_limit="-2.28" upper_limit="5.5"/>
                    <measurement group_id="O5" value="1.79" lower_limit="-0.78" upper_limit="4.36"/>
                    <measurement group_id="O6" value="4.52" lower_limit="1.73" upper_limit="7.3"/>
                    <measurement group_id="O7" value="2.79" lower_limit="-1" upper_limit="6.59"/>
                    <measurement group_id="O8" value="3.72" lower_limit="1" upper_limit="6.44"/>
                    <measurement group_id="O9" value="0.03" lower_limit="-2.21" upper_limit="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" lower_limit="-1.34" upper_limit="6.76"/>
                    <measurement group_id="O2" value="1.8" lower_limit="-2.09" upper_limit="5.69"/>
                    <measurement group_id="O3" value="1.84" lower_limit="-0.75" upper_limit="4.44"/>
                    <measurement group_id="O4" value="0.25" lower_limit="-3.64" upper_limit="4.15"/>
                    <measurement group_id="O5" value="3.88" lower_limit="1.27" upper_limit="6.5"/>
                    <measurement group_id="O6" value="3.37" lower_limit="0.58" upper_limit="6.15"/>
                    <measurement group_id="O7" value="4.52" lower_limit="0.85" upper_limit="8.19"/>
                    <measurement group_id="O8" value="4.08" lower_limit="1.36" upper_limit="6.8"/>
                    <measurement group_id="O9" value="0.18" lower_limit="-2.07" upper_limit="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" lower_limit="-0.79" upper_limit="7.32"/>
                    <measurement group_id="O2" value="0.19" lower_limit="-3.7" upper_limit="4.08"/>
                    <measurement group_id="O3" value="1.99" lower_limit="-0.65" upper_limit="4.63"/>
                    <measurement group_id="O4" value="1.55" lower_limit="-2.34" upper_limit="5.45"/>
                    <measurement group_id="O5" value="3.02" lower_limit="0.4" upper_limit="5.63"/>
                    <measurement group_id="O6" value="4.44" lower_limit="1.66" upper_limit="7.23"/>
                    <measurement group_id="O7" value="2.34" lower_limit="-1.33" upper_limit="6.01"/>
                    <measurement group_id="O8" value="4.13" lower_limit="1.41" upper_limit="6.86"/>
                    <measurement group_id="O9" value="-0.36" lower_limit="-2.63" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number Analyzed = those participants who were evaluable at the specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</title>
            <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 and 6 Combined: Placebo</title>
            <description>All participants in group 4, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, Number Analyzed = those participants who were evaluable at the specified time points for each group, respectively.</population>
          <units>percent predicted of FEV1</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Baseline Through Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="-1.42" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.31" lower_limit="-0.19" upper_limit="4.8"/>
                    <measurement group_id="O3" value="1.47" lower_limit="-1.2" upper_limit="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="-1.33" upper_limit="4.08"/>
                    <measurement group_id="O2" value="1.95" lower_limit="-0.93" upper_limit="4.82"/>
                    <measurement group_id="O3" value="1.09" lower_limit="-1.97" upper_limit="4.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-1.55" upper_limit="3.95"/>
                    <measurement group_id="O2" value="2.52" lower_limit="-0.36" upper_limit="5.4"/>
                    <measurement group_id="O3" value="1.37" lower_limit="-1.69" upper_limit="4.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" lower_limit="-2.38" upper_limit="3.11"/>
                    <measurement group_id="O2" value="3.21" lower_limit="0.33" upper_limit="6.08"/>
                    <measurement group_id="O3" value="1.73" lower_limit="-1.39" upper_limit="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" lower_limit="-1.97" upper_limit="3.6"/>
                    <measurement group_id="O2" value="1.56" lower_limit="-1.32" upper_limit="4.44"/>
                    <measurement group_id="O3" value="1.67" lower_limit="-1.45" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 7: Placebo</title>
            <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 7: VX-661 100 mg qd</title>
            <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug.</population>
          <units>percent predicted of FEV1</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Baseline Through Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="-5.04" upper_limit="7.83"/>
                    <measurement group_id="O2" value="4.6" lower_limit="1.17" upper_limit="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-3.55" upper_limit="9.55"/>
                    <measurement group_id="O2" value="4.14" lower_limit="0.65" upper_limit="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.98" lower_limit="-5.56" upper_limit="7.53"/>
                    <measurement group_id="O2" value="5.22" lower_limit="1.73" upper_limit="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" lower_limit="-3.83" upper_limit="9.27"/>
                    <measurement group_id="O2" value="3.88" lower_limit="0.39" upper_limit="7.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.12" lower_limit="-7.66" upper_limit="5.43"/>
                    <measurement group_id="O2" value="5.16" lower_limit="1.67" upper_limit="8.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1 (Liter [L]) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VX-661 10 mg qd</title>
            <description>All participants in group 1 who received VX-661 10 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2a: VX-661 30 mg qd</title>
            <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Group 3a: VX-661 100 mg qd</title>
            <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O7">
            <title>Group 5a: VX-661 150 mg qd</title>
            <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O8">
            <title>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Group 1-5b Combined Placebo</title>
            <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a and 5b who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1 (Liter [L]) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="17"/>
                <count group_id="O9" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PB Through Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.02" upper_limit="0.26"/>
                    <measurement group_id="O2" value="0.07" lower_limit="-0.05" upper_limit="0.19"/>
                    <measurement group_id="O3" value="0.05" lower_limit="-0.03" upper_limit="0.13"/>
                    <measurement group_id="O4" value="0.04" lower_limit="-0.08" upper_limit="0.16"/>
                    <measurement group_id="O5" value="0.1" lower_limit="0.02" upper_limit="0.18"/>
                    <measurement group_id="O6" value="0.14" lower_limit="0.06" upper_limit="0.23"/>
                    <measurement group_id="O7" value="0.1" lower_limit="-0.01" upper_limit="0.21"/>
                    <measurement group_id="O8" value="0.12" lower_limit="0.04" upper_limit="0.21"/>
                    <measurement group_id="O9" value="0.01" lower_limit="-0.06" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="17"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="17"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="-0.04" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.02" lower_limit="-0.13" upper_limit="0.16"/>
                    <measurement group_id="O3" value="0.02" lower_limit="-0.08" upper_limit="0.12"/>
                    <measurement group_id="O4" value="0.09" lower_limit="-0.06" upper_limit="0.24"/>
                    <measurement group_id="O5" value="0.1" lower_limit="0" upper_limit="0.19"/>
                    <measurement group_id="O6" value="0.11" lower_limit="0.01" upper_limit="0.21"/>
                    <measurement group_id="O7" value="0.02" lower_limit="-0.12" upper_limit="0.16"/>
                    <measurement group_id="O8" value="0.08" lower_limit="-0.02" upper_limit="0.18"/>
                    <measurement group_id="O9" value="-0.01" lower_limit="-0.09" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="8"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.05" upper_limit="0.34"/>
                    <measurement group_id="O2" value="0.14" lower_limit="-0.01" upper_limit="0.28"/>
                    <measurement group_id="O3" value="0.03" lower_limit="-0.07" upper_limit="0.12"/>
                    <measurement group_id="O4" value="0.04" lower_limit="-0.11" upper_limit="0.19"/>
                    <measurement group_id="O5" value="0.05" lower_limit="-0.04" upper_limit="0.15"/>
                    <measurement group_id="O6" value="0.17" lower_limit="0.06" upper_limit="0.27"/>
                    <measurement group_id="O7" value="0.11" lower_limit="-0.03" upper_limit="0.25"/>
                    <measurement group_id="O8" value="0.12" lower_limit="0.02" upper_limit="0.23"/>
                    <measurement group_id="O9" value="0.02" lower_limit="-0.07" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="-0.03" upper_limit="0.27"/>
                    <measurement group_id="O2" value="0.08" lower_limit="-0.06" upper_limit="0.23"/>
                    <measurement group_id="O3" value="0.07" lower_limit="-0.03" upper_limit="0.17"/>
                    <measurement group_id="O4" value="0" lower_limit="-0.15" upper_limit="0.15"/>
                    <measurement group_id="O5" value="0.14" lower_limit="0.04" upper_limit="0.23"/>
                    <measurement group_id="O6" value="0.13" lower_limit="0.02" upper_limit="0.23"/>
                    <measurement group_id="O7" value="0.18" lower_limit="0.04" upper_limit="0.31"/>
                    <measurement group_id="O8" value="0.14" lower_limit="0.04" upper_limit="0.24"/>
                    <measurement group_id="O9" value="0.02" lower_limit="-0.06" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="-0.02" upper_limit="0.28"/>
                    <measurement group_id="O2" value="0.03" lower_limit="-0.11" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.08" lower_limit="-0.02" upper_limit="0.18"/>
                    <measurement group_id="O4" value="0.04" lower_limit="-0.11" upper_limit="0.18"/>
                    <measurement group_id="O5" value="0.1" lower_limit="0.01" upper_limit="0.2"/>
                    <measurement group_id="O6" value="0.16" lower_limit="0.06" upper_limit="0.27"/>
                    <measurement group_id="O7" value="0.09" lower_limit="-0.05" upper_limit="0.23"/>
                    <measurement group_id="O8" value="0.15" lower_limit="0.05" upper_limit="0.26"/>
                    <measurement group_id="O9" value="0.01" lower_limit="-0.08" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</title>
            <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 and 6 Combined: Placebo</title>
            <description>All participants in group 4, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Baseline Through Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.07" upper_limit="0.11"/>
                    <measurement group_id="O2" value="0.09" lower_limit="-0.01" upper_limit="0.18"/>
                    <measurement group_id="O3" value="0.07" lower_limit="-0.04" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.07" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.06" lower_limit="-0.05" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.05" lower_limit="-0.06" upper_limit="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-0.07" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.01" upper_limit="0.21"/>
                    <measurement group_id="O3" value="0.06" lower_limit="-0.05" upper_limit="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.11" upper_limit="0.1"/>
                    <measurement group_id="O2" value="0.13" lower_limit="0.02" upper_limit="0.24"/>
                    <measurement group_id="O3" value="0.08" lower_limit="-0.04" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.08" upper_limit="0.13"/>
                    <measurement group_id="O2" value="0.06" lower_limit="-0.05" upper_limit="0.17"/>
                    <measurement group_id="O3" value="0.08" lower_limit="-0.04" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
        <time_frame>Baseline, Day 7, Day 14, Day 21, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 7: Placebo</title>
            <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 7: VX-661 100 mg qd</title>
            <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FEV1 (L) From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Baseline Through Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" lower_limit="-0.16" upper_limit="0.34"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.03" upper_limit="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="-0.11" upper_limit="0.39"/>
                    <measurement group_id="O2" value="0.15" lower_limit="0.01" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="-0.17" upper_limit="0.33"/>
                    <measurement group_id="O2" value="0.18" lower_limit="0.05" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="-0.11" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.13" lower_limit="-0.01" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" lower_limit="-0.26" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.05" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b</title>
        <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.</description>
        <time_frame>Baseline, Day 14, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VX-661 10 mg qd</title>
            <description>All participants in group 1 who received VX-661 10 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2a: VX-661 30 mg qd</title>
            <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Group 3a: VX-661 100 mg qd</title>
            <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O7">
            <title>Group 5a: VX-661 150 mg qd</title>
            <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O8">
            <title>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O9">
            <title>Group 1-5b Combined Placebo</title>
            <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a and 5b who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 1-5b</title>
          <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="9"/>
                <count group_id="O8" value="17"/>
                <count group_id="O9" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PB Through Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" lower_limit="-4.38" upper_limit="12.43"/>
                    <measurement group_id="O2" value="5.54" lower_limit="-2.72" upper_limit="13.79"/>
                    <measurement group_id="O3" value="3.8" lower_limit="-1.74" upper_limit="9.35"/>
                    <measurement group_id="O4" value="0.61" lower_limit="-7.64" upper_limit="8.86"/>
                    <measurement group_id="O5" value="3.52" lower_limit="-2.02" upper_limit="9.06"/>
                    <measurement group_id="O6" value="5.15" lower_limit="-0.88" upper_limit="11.19"/>
                    <measurement group_id="O7" value="2.58" lower_limit="-5.21" upper_limit="10.37"/>
                    <measurement group_id="O8" value="7.62" lower_limit="1.78" upper_limit="13.45"/>
                    <measurement group_id="O9" value="1.69" lower_limit="-3.1" upper_limit="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="18"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.67" lower_limit="-2.9" upper_limit="16.25"/>
                    <measurement group_id="O2" value="4.84" lower_limit="-4.73" upper_limit="14.41"/>
                    <measurement group_id="O3" value="4.29" lower_limit="-2.09" upper_limit="10.67"/>
                    <measurement group_id="O4" value="0.27" lower_limit="-9.3" upper_limit="9.83"/>
                    <measurement group_id="O5" value="2.81" lower_limit="-3.56" upper_limit="9.19"/>
                    <measurement group_id="O6" value="4.41" lower_limit="-2.58" upper_limit="11.4"/>
                    <measurement group_id="O7" value="4.13" lower_limit="-4.9" upper_limit="13.16"/>
                    <measurement group_id="O8" value="7.13" lower_limit="0.37" upper_limit="13.89"/>
                    <measurement group_id="O9" value="0.53" lower_limit="-4.99" upper_limit="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="9"/>
                    <count group_id="O8" value="16"/>
                    <count group_id="O9" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="-8.7" upper_limit="11.45"/>
                    <measurement group_id="O2" value="6.23" lower_limit="-3.34" upper_limit="15.8"/>
                    <measurement group_id="O3" value="3.31" lower_limit="-3.21" upper_limit="9.84"/>
                    <measurement group_id="O4" value="0.95" lower_limit="-8.61" upper_limit="10.52"/>
                    <measurement group_id="O5" value="4.22" lower_limit="-2.29" upper_limit="10.74"/>
                    <measurement group_id="O6" value="5.9" lower_limit="-1.1" upper_limit="12.89"/>
                    <measurement group_id="O7" value="1.03" lower_limit="-8" upper_limit="10.06"/>
                    <measurement group_id="O8" value="8.1" lower_limit="1.34" upper_limit="14.87"/>
                    <measurement group_id="O9" value="2.85" lower_limit="-2.76" upper_limit="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6</title>
        <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
        <time_frame>Baseline, Day 14, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</title>
            <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 4 and 6 Combined: Placebo</title>
            <description>All participants in group 4, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 6</title>
          <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. As per planned analysis, participants who received placebo in Group 4 and 6 were combined and compared with Group 6.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Baseline Through Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="-4.44" upper_limit="6.19"/>
                    <measurement group_id="O2" value="1.91" lower_limit="-3.5" upper_limit="7.33"/>
                    <measurement group_id="O3" value="1.65" lower_limit="-4.18" upper_limit="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" lower_limit="-3.97" upper_limit="8.02"/>
                    <measurement group_id="O2" value="0.87" lower_limit="-5.25" upper_limit="6.99"/>
                    <measurement group_id="O3" value="2.78" lower_limit="-3.76" upper_limit="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" lower_limit="-6.27" upper_limit="5.72"/>
                    <measurement group_id="O2" value="2.96" lower_limit="-3.16" upper_limit="9.08"/>
                    <measurement group_id="O3" value="0.53" lower_limit="-6.18" upper_limit="7.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7</title>
        <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.</description>
        <time_frame>Baseline, Day 14, Day 28</time_frame>
        <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 7: Placebo</title>
            <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 7: VX-661 100 mg qd</title>
            <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline to Each Visit and From Baseline Through Study Day 28 for Group 7</title>
          <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.</description>
          <population>The analysis was done using FAS which included all randomized participants who received at least 1 dose of study drug. Here, 'Number Analyzed' = those participants who were evaluable at the specified time points for each group, respectively.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-Baseline Through Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.02" lower_limit="-13.52" upper_limit="7.47"/>
                    <measurement group_id="O2" value="3.79" lower_limit="-1.78" upper_limit="9.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" lower_limit="-10.64" upper_limit="14.3"/>
                    <measurement group_id="O2" value="5.24" lower_limit="-1.56" upper_limit="12.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.87" lower_limit="-20.34" upper_limit="4.6"/>
                    <measurement group_id="O2" value="2.33" lower_limit="-4.24" upper_limit="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 After Administration of VX-661 Monotherapy</title>
        <description>Participants who received VX-661 monotherapy (Group 1, 2a, 3a and 5a) were analyzed for this outcome measure. PK analysis (AUC0-24h) was not planned for placebo reporting arms.</description>
        <time_frame>Day 28</time_frame>
        <population>The analysis was done using Pharmacokinetics (PK) Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: VX-661 10 mg qd</title>
            <description>All participants in group 1 who received VX-661 10 mg tablet orally qd for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 2a: VX-661 30 mg qd</title>
            <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 3a: VX-661 100 mg qd</title>
            <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Group 5a: VX-661 150 mg qd</title>
            <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661 After Administration of VX-661 Monotherapy</title>
          <description>Participants who received VX-661 monotherapy (Group 1, 2a, 3a and 5a) were analyzed for this outcome measure. PK analysis (AUC0-24h) was not planned for placebo reporting arms.</description>
          <population>The analysis was done using Pharmacokinetics (PK) Set.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6260" spread="2650"/>
                    <measurement group_id="O2" value="23000" spread="6550"/>
                    <measurement group_id="O3" value="88100" spread="51100"/>
                    <measurement group_id="O4" value="98900" spread="20200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-24h of VX-661 and AUC0-12h of Ivacaftor After Administration of VX-661 in Combination With Ivacaftor</title>
        <description>Participants who received VX-661 in combination with Ivacaftor (Group 2b, 3b, 4, 5b, 6a, 6d and 7) were analyzed for this outcome measure. PK analysis was not planned for placebo reporting arms.</description>
        <time_frame>Day 28</time_frame>
        <population>The analysis was done using PK Set.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O2">
            <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O3">
            <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
            <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O4">
            <title>Group 5b: VX-661 150 mg qd/ Ivacaftor 150 mg q12h</title>
            <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O5">
            <title>Group 6a: VX-661 100 mg qd/ Ivacaftor 50 mg q12h</title>
            <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O6">
            <title>Group 6d: VX-661 50 mg q12h/ Ivacaftor 150 mg q12h</title>
            <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
          </group>
          <group group_id="O7">
            <title>Group 7: VX-661 100 mg qd</title>
            <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician prescribed Kalydeco for up to 28 days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-24h of VX-661 and AUC0-12h of Ivacaftor After Administration of VX-661 in Combination With Ivacaftor</title>
          <description>Participants who received VX-661 in combination with Ivacaftor (Group 2b, 3b, 4, 5b, 6a, 6d and 7) were analyzed for this outcome measure. PK analysis was not planned for placebo reporting arms.</description>
          <population>The analysis was done using PK Set.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="17"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-24h of VX-661</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="17"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8950" spread="2370"/>
                    <measurement group_id="O2" value="26300" spread="5870"/>
                    <measurement group_id="O3" value="82700" spread="23300"/>
                    <measurement group_id="O4" value="138000" spread="49700"/>
                    <measurement group_id="O5" value="77600" spread="17800"/>
                    <measurement group_id="O6" value="73300" spread="22900"/>
                    <measurement group_id="O7" value="90600" spread="30800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-12h of Ivacaftor</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="15"/>
                    <count group_id="O6" value="14"/>
                    <count group_id="O7" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10100" spread="4380"/>
                    <measurement group_id="O2" value="11700" spread="4870"/>
                    <measurement group_id="O3" value="10900" spread="3890"/>
                    <measurement group_id="O4" value="16000" spread="10400"/>
                    <measurement group_id="O5" value="3690" spread="1460"/>
                    <measurement group_id="O6" value="11700" spread="5450"/>
                    <measurement group_id="O7" value="12400" spread="6170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Start of study drug through the Follow-up Visit (Up to Day 56)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1-6d Combined: Placebo</title>
          <description>All participants in group 1, 2a, 2b, 3a, 3b, 4, 5a, 5b, 6a and 6d who received placebo matched to VX-661 tablet and/or placebo matched to ivacaftor tablet for up to 28 days.</description>
        </group>
        <group group_id="E2">
          <title>Group 1: VX-661 10 mg qd</title>
          <description>All participants in group 1 who received VX-661 10 milligram (mg) tablet orally qd for up to 28 days.</description>
        </group>
        <group group_id="E3">
          <title>Group 2a: VX-661 30 mg qd</title>
          <description>All participants in group 2a who received VX-661 30 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
        </group>
        <group group_id="E4">
          <title>Group 2b: VX-661 10 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 2b who received VX-661 10 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="E5">
          <title>Group 3a: VX-661 100 mg qd</title>
          <description>All participants in group 3a who received VX-661 100 mg tablet orally qd and placebo matched to Ivacaftor tablet q12h for up to 28 days.</description>
        </group>
        <group group_id="E6">
          <title>Group 3b: VX-661 30 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 3b who received VX-661 30 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="E7">
          <title>Group 4: VX-661 100 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 4 who received VX-661 100 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="E8">
          <title>Group 5a: VX-661 150 mg qd</title>
          <description>All participants in group 5a who received VX-661 150 mg tablet orally qd for up to 28 days.</description>
        </group>
        <group group_id="E9">
          <title>Group 5b: VX-661 150 mg qd/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 5b who received VX-661 150 mg tablet qd and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="E10">
          <title>Group 6a: VX-661 100 mg qd/Ivacaftor 50 mg q12h</title>
          <description>All participants in group 6a who received VX-661 100 mg tablet qd and Ivacaftor 50 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="E11">
          <title>Group 6d: VX-661 50 mg q12h/Ivacaftor 150 mg q12h</title>
          <description>All participants in group 6d who received VX-661 50 mg tablet and Ivacaftor 150 mg tablet q12h orally for up to 28 days.</description>
        </group>
        <group group_id="E12">
          <title>Group 7: Placebo</title>
          <description>All participants in group 7 who received placebo matched to VX-661 tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
        </group>
        <group group_id="E13">
          <title>Group 7: VX-661 100 mg qd</title>
          <description>All participants in group 7 who received VX-661 100 mg tablet orally qd in combination with physician-prescribed Kalydeco for up to 28 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic fibrosis related diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Conjunctival irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Change of bowel habit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Faeces discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Application site rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vessel puncture site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Post concussion syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastrointestinal examination abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary casts present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urine colour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vitamin E deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vitamin K deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Thinking abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Respiration abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Increased viscosity of bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Increased bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Respiratory tract irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash follicular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Red man syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Restriction Description: PI is free to publish results of the study after (1)first multi-center publication, (2)if sponsor elects not to publish the results, or(3)18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pharmacokinetic (PK) final data are not yet available. Once the data are available for PK endpoints, the posting will be updated to include the same.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Monitor</name_or_title>
      <organization>Vertex Pharmaceuticals Incorporated</organization>
      <phone>617-341-6777</phone>
      <email>medicalinfo@vrtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

